क्यूआर कोड

Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.

<h4>Background</h4>Ketamine at subanaesthetic dosages (≤0.5mg/kg) exhibits rapid onset (over hours to days) antidepressant effects against major depressive disorder in people who are otherwise well. However, its safety, tolerability and efficacy are not known for major depressive disorder in people...

पूर्ण विवरण

में बचाया:
मुख्य लेखकों: Wei Lee, Caitlin Sheehan, Richard Chye, Sungwon Chang, Adam Bayes, Colleen Loo, Brian Draper, Meera R Agar, David C Currow
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Public Library of Science (PLoS) 2023-01-01
श्रृंखला:PLoS ONE
ऑनलाइन पहुंच:https://doi.org/10.1371/journal.pone.0290876
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन